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A B S T R A C T
Aplastic anaemia is featured by bone marrow
hypocellularity and peripheral pancytopenia and is a
potentially fatal disease. In recent years, insight in its
pathogenesis has increased. It appears that activated
autoreactive T lymphocytes induce apoptosis of
haematopoietic stem cells resulting in a hypocellular
bone marrow. Nowadays, it can be treated by stem cell
transplantation or immunosuppressive therapy. This
review focuses on the pathophysiology and treatment of
aplastic anaemia.
I N T R O D U C T I O N
Aplastic anaemia is a serious medical disorder which, when
untreated, has a median survival of less than ten months1
due to infections and haemorrhage. Fortunately, in the
last decades its prognosis has improved dramatically and
most patients now achieve durable responses. Aplastic
anaemia is featured by hypoplasia of the bone marrow and
peripheral pancytopenia (figure 1). The most commonly
used criteria for the diagnosis aplastic anaemia are marrow
cellularity of less than 25% of normal or less than 50%
with haematopoietic cells representing less than 30% of
the residual cells and at least two of the following peripheral
blood counts: neutrophil count of less than 0.5 x 109/l,
platelet count of less than 20 x 109/l, and/or anaemia
with a reticulocyte count of less than 1%.2
Aplastic anaemia can be due to congenital (20%) or
acquired causes (80%) (table 1). Congenital diseases leading
to aplastic anaemia will not be further discussed here.
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Figure 1
Bone marrow biopsy from a patient with aplastic
anaemia (A) compared with a normal bone marrow (B)
A
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Causes of acquired aplastic anaemia are very diverse, the
most common being iatrogenic causes such as radiation
and drugs directly cytotoxic to the bone marrow. Some
haematological malignancies or infections can present as
aplastic anaemia. In some cases, myelodysplastic syndrome
(MDS) can occur with a hypocellular bone marrow and
peripheral pancytopenia. In these cases, it is sometimes
difficult to distinguish between MDS and aplastic anaemia.
Distinction by cytogenetic analysis is not always possible
because in about 4% of the patients with aplastic anaemia
cytogenetic abnormalities are found, sometimes similar
to those seen in patients suffering from MDS.3
Furthermore, not all patients with evident morphological
MDS have cytogenetic alterations. Some institutions
consider patients with findings fulfilling the diagnosis of
aplastic anaemia and with cytogenetic abnormalities as
MDS, independent of the marrow morphology.4
The management of acquired aplastic anaemia due to
such causes as aforementioned involves treatment of the
underlying cause. This review, however, will focus on the
remaining causes of acquired aplastic anaemia in which
haematopoietic stem cell damage due to autoreactive
T lymphocytes is the central event but in which the exact
cause that elicits this reaction is largely unknown.
E P I D E M I O L O G Y  A N D  A E T I O L O G Y
Aplastic anaemia is a rare disease with a reported incidence
of approximately 2 per 1 x 106 annually in Europe. In Asia,
it occurs three times more often with an incidence of 5 to
7 per 1 x 106 annually.5
As will be described below, autoreactive T lymphocytes
are thought to play an important role in the pathogenesis
of aplastic anaemia. As in other autoimmune diseases, an
association with certain HLA alleles has been described
in patients with aplastic anaemia. In these patients, an
increased HLA-DR2 frequency of 58% is found, versus
28% in the normal population.6
Because prognosis of aplastic anaemia is related to the
number of neutrophils, aplastic anaemia is divided into
nonsevere aplastic anaemia with neutrophils above 
0.5 x 109/l, severe aplastic anaemia with neutrophils
between 0.2 and 0.5 x 109/l, and very severe aplastic
anaemia with neutrophils lower than 0.2 x 109/l.7
The aetiology of acquired aplastic anaemia is very diverse.
Aplastic anaemia usually occurs without a suggestive
prior history and is labelled idiopathic. However, in some
cases a clear inciting event can be identified. Many drugs
and chemicals have been described as causing aplastic
anaemia by a rare idiosyncratic reaction. The most well
known are drugs such as chloramphenicol, but widely
used medications as furosemide and allopurinol have also
been associated with aplastic anaemia.8
Approximately 5 to 10% of aplastic anaemia occurs after
an episode of hepatitis in which no known viral pathogen
or a relation with drugs can be identified.9 Patients who
receive a liver transplantation for hepatic failure caused by
such a seronegative fulminant hepatitis are at a high risk
of developing aplastic anaemia. It occurs in about 25% of
these patients.10 It is plausible that a not yet identified
infectious agent is involved. Also parvovirus B19 is
associated with aplastic anaemia.11
Relationships with pregnancy12 and autoimmune disorders
such as eosinophilic fasciitis have also been reported.
However, whatever the underlying cause, it does not seem
to affect the response to treatment.13
P A T H O G E N E S I S
There are several indications that aplastic anaemia is due
to a stem cell dysfunction. When stem cells of patients
are seeded onto irradiated normal stromal cells in vitro, a
reduced number of colony-forming units (CFU) is seen. In
contrast, normal CFU forming is observed after placement
of normal CD34-positive cells into stromal cells of patients.14
Therefore stromal dysfunction appears unlikely.
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Furthermore, CD34-positive cells are decreased in blood
and bone marrow,15 while in the remaining stem cells an
increased percentage of apoptotic cells is seen.16
Evidence is mounting that a T-cell-mediated reaction may
be responsible for the stem cell destruction. In bone marrow
of patients an increased number of activated CD8
lymphocytes are seen.17 Moreover, T cells of patients are
capable of reducing CFU forming in vitro, while depletion
of these T cells restores CFU forming.18 Furthermore,
T cells of patients produce cytokines such as interferon-
and tumour necrosis factor- and increased expression of
these cytokines has been shown in the bone marrow of
patients.19 These cytokines can suppress stem cell pro-
liferation and induce apoptosis of stem cells.20 The
cytokine-induced apoptosis can occur directly and indirectly
by the Fas-Fas-ligand system. Interferon- and tumour
necrosis factor- are capable of inducing Fas expression
on stem cells, and increased Fas expression is found in
bone marrow of patients.21 Fas ligand, which can be found
on activated T lymphocytes, can subsequently induce
apoptosis of these Fas-expressing stem cells.
The important role of these cytokines is underscored by
the observation that in a murine model of aplastic
anaemia, pancytopenia can be ameliorated by treatment
with antibodies against IFN.22
So, at present the hypothesis is that activated CD8
lymphocytes induce apoptosis of stem cells directly as
well as by cytokines produced by these CD8 lymphocytes.
However, the exact mechanisms inducing this immune
reaction are unknown. Because there are so many diverse
causes of aplastic anaemia, it can be assumed that there
are also various mechanisms leading to T-cell activation.
For instance, after a viral infection, molecular mimicry
may be involved and in case of an idiosyncratic drug
reaction, hapten forming. Recently, it was found that the
P-glycoprotein function of stem cells was reduced in
patients with drug-induced aplastic anaemia compared
with patients with aplastic anaemia due to another cause.23
This decreased function of P glycoprotein, which is involved
in drug efflux, may lead to increased accumulation of
drugs in stem cells and subsequently result in increased
cytotoxicity in these cells. Therefore, patients with
decreased P-glycoprotein function might be more prone
to develop drug-induced aplastic anaemia.
In a subset of patients a mechanism other than immune-
mediated stem cell damage may be involved. Recently, in
some patients with aplastic anaemia a germ-line mutation
in the gene encoding for the RNA component of telomerase
has been shown.24 This mutation results in decreased
telomerase activity and subsequently shorter telomers,
which may ultimately lead to reduced survival of stem
cells and to aplastic anaemia.
T R E A T M E N T
Allogeneic stem cell transplantation (allo-SCT) using bone
marrow as treatment for aplastic anaemia was first
applied in the early seventies. Nowadays, peripheral stem
cells are being increasingly used. When successful, a fast
haematological response is seen after allo-SCT with
neutrophils above 0.5 x 109/l and platelets above 20 x 109/l
after a median of about 15 and 20 days, respectively.
However, allo-SCT can be accompanied with severe toxicity.
The main mortality and morbidity is due to graft failure,
drug-related toxicity, infections and the occurrence of
acute and/or chronic graft-versus-host disease (GVHD).
Recently the European Group for Blood and Marrow
Transplantation (EBMT) retrospectively analysed the data
of 2002 patients with aplastic anaemia who had received
an allo-SCT between 1976 and 1998.25 Most patients
(85%) received a transplant from an HLA-identical sibling,
13% from a matched unrelated donor, and 2% from an
identical twin. Graft type clearly affected survival in these
three groups with 66, 37, and 91% respectively. Data on
responses were not given.
Mortality was strongly associated with age. In patients
treated with allo-SCT from an HLA-identical sibling between
1990 to 1998, survival rates for patients aged <16, between
16-40, and >40 years were 77, 68, and 54%, respectively.
Remarkable was the improvement in time with an increase
in survival from 57% up to 1990 to 76% after 1990. This
improvement is mainly caused by a decline in the occur-
rence of acute GVHD due to more effective prophylaxis,
better matching, and improved supportive care.
In patients who are not candidates for SCT, immuno-
suppressive therapy (IST) is employed. Mathe et al. reported
autologous bone marrow recovery in some patients who
rejected their grafts. These authors speculated that the
antithymocyte globulin (ATG) used in the conditioning
regimen had induced an anti-immune process.26 Since
then, several randomised studies have been carried out.
Drugs studied in a randomised setting are ATG,
cyclosporine A (CsA), androgens, corticosteroids, growth
factors and cyclophosphamide (table 2). However, these
trials are very difficult to compare due to differences in
inclusion criteria, definitions for response, time of follow-up,
and treatment regimens. Until now, the best results have
been reported with the combination of ATG and CsA. Both
horse and rabbit ATG are frequently used and both are
licensed for treatment in the United States. Data comparing
both types ATG and several doses are not available. In
our centre, the combination treatment consists of horse
ATG 15 mg/kg administrated daily for five days and CsA
for at least three months. Initially, CsA is administered
orally twice daily at 3 mg/kg. Dosing of CsA is adjusted to
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maintain trough levels of 100 to 300 ng/ml from day 1 to
28; from day 28 target trough levels are 50 to 150 ng/ml.
CsA can be tapered off when there is a good response,
and if necessary, restarted in case of relapse. During
administration of ATG, corticosteroids are given for
attenuating ATG-induced side effects. The corticosteroids
themselves probably have a minor effect in aplastic
anaemia.34
Good responses by this combination treatment, defined as
neutrophils above 1.0 x 109/l and transfusion independence,
are obtained in 60 to 80% of the patients. These responses,
however, are rather slow and usually take three to six months
to occur. Furthermore the response is often not complete
(normalisation of blood counts) and about 30 to 40%
show a relapse after a few years. Over time, five-year survival
has improved because of better supportive care. In 1981, the
five-year survival was 58% compared with 75% in 1991.39
In case of relapse or nonresponding disease after a first
course, a second course of IST can be given. This second
course is successful in approximately 50% of the patients.40
Concern for development of serum sickness by repeated
courses of ATG was examined by Tichelli et al.40 These
authors showed that a repeated administration of horse
ATG is safe and well tolerated. Serum sickness occurred
earlier but not more often.40 When disease is refractory to
repeated courses of IST, an allo-SCT can be considered
when the patient was not a candidate for primary treatment
with SCT.
L O N G - T E R M  E F F E C T S
Because both allo-SCT and IST have rather good effects
in the short term, long-term effects are important.
About 10% of the patients treated with IST for aplastic
anaemia develop paroxysmal nocturnal haemoglobinuria
(PNH) with haemolytic anaemia.41 This does not occur in
patients treated with allo-SCT. PNH is due to a mutation
in a gene encoding for a protein which is involved in the
synthesis of a glycosylphosphatidylinositol anchor (GPI)
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Table 2
Results of trials comparing different regimens of IST for aplastic anaemia. Definitions for response rate and follow-up
for survival differs between studies
AUTHOR N TREATMENT RESPONSE RATE (%) SURVIVAL (%) REMARKS
Champlin27 21 ATG 52* 62
21 Control 0 62
Camitta28 29 ATG 69* 76*
13 Control 23 31
Champlin29 26 ATG/andr 42 55
27 ATG 44 50
Doney30 12 mcAb 8 58
13 ATG 31 77
Kaltwasser31 15 ATG/andr 73 87
15 ATG 31 43
Frickhofen32 43 ATG/Mpr/CsA 65* 64
41 ATG/Mpr 39 58
Gluckman33 48 ATG/Mpr 30 64
46 CsA 32 70
Doney34 31 ATG/HD-Mpr/andr 48 47
33 ATG/LD-Mpr/andr 36 43
Bacigalupo35 69 ATG/Mpr/andr 56* 71
65 ATG/Mpr 40 65
Marsh36 54 ATG/CsA 74* 91
61 CsA 46 93
Kojima37 35 ATG/CsA/andr/G-CSF 55 91 Study in
34 ATG/CsA/andr 77 93 children
Tisdale38 15 CsA/cycloph 46 NR Premarurely terminated;
16 ATG/CsA 75 NR excess mortality in
cyclophosphamide group
ATG = antithymocyte globulin, andr = androgen, mcAb = murine antihuman T cell monoclonal antibody, Mpr = methylprednisolone, CsA = cyclosporine A,
HD-Mpr = high-dose methylprednisolone, LD-Mpr = low-dose methylprednisolone, cycloph = cyclophosphamide, NR = not reported. * Significant difference
(p<0.05).
responsible for the attachment of several proteins to the
cell membrane. PNH usually presents with haemolytic
anaemia but in 20 to 50% of the cases of aplastic
anaemia a decreased expression of GPI-anchored proteins
is found suggesting a strong link between these two
conditions.42 PNH as a long-term side effect is only found
in patients who initially present with aplastic anaemia
combined with a decreased GPI-anchored protein
expression.42 An explanation for this increased incidence
of PNH after IST could be that stem cell clones with
decreased expression of GPI-anchored proteins have a
growth advantage compared with normal stem cells in
aplastic anaemia. Stem cells with GPI deficiency, which
can also be found in normal people,43 appear to be less
prone to apoptosis than normal cells.44 In a disorder like
aplastic anaemia, in which apoptosis-induced stem cell
damage is important, this phenomenon may subsequently
lead to a growth advantage for these GPI-deficient cells
and ultimately to PNH.
Socie et al.45 compared the incidence of malignant tumours
after treatment for aplastic anaemia. It was found that the
number of cancers was clearly increased compared with
the general population, especially the occurrence of acute
leukaemia (115 times in patients treated with IST, 29 times
in patients who received a transplantation). The incidence
of the development of solid tumours was only significantly
increased in patients who were treated with allo-SCT
(5.7 times). Comparing both treatments, especially the
occurrence of acute leukaemia and MDS was clearly
increased in patients who were treated with IST compared
with those who received allo-SCT. Altogether, this results
in a cumulative ten-year incidence of all cancers of 18.8%
in patients treated with IST and 3.1% in those who
received an allo-SCT.45 The strongly increased incidence
of cancer in patients treated with IST is reflected in the
survival curve which is still declining after a follow-up of
five years, while the curve of patients treated with allo-SCT
reaches a plateau after this time period.46
The reason for the strongly increased incidence of cancer
is not exactly known. The incidence of solid cancer after
transplantation is associated to the use of radiation in the
conditioning regimen.45 The strong increase of MDS in
IST can be due to the fact that the initial diagnosis was
not aplastic anaemia but hypocellular MDS. Another
explanation could be that the remaining stem cells, not
affected by the immune system, have an increased cell
cycle to compensate for the damaged stem cells. The
observed shortening of telomeres in peripheral leucocytes
of patients is in agreement with this hypothesis.47 The
increased cell cycle results in an augmented number of
mutations which may lead to either MDS or acute
leukaemia. Other possible mechanisms described as
being related to the increased AML/MDS incidence are
multiple courses of ATG45 and the use of G-CSF.48
B E S T  P R I M A R Y  T R E A T M E N T
An important remaining question is what the first-line
therapy of a patient presenting with aplastic anaemia
should be. Several studies comparing the efficacy of allo-SCT
and IST have been performed (table 3). Again, these studies
are difficult to compare. Most studies did not find a
difference between these treatments, except for one study
performed in children which showed an advantage for
allo-SCT.52 However, the number of patients studied in
these trials was rather small.
Therefore, the European Blood and Marrow Transplantation
Group (EBMT) retrospectively analysed data on 1765 patients
with acquired aplastic anaemia.40 Comparing both
treatments, it appears that especially in younger patients
up to 40 years with a strongly decreased number of
neutrophils (<0.3 x 109/l), allo-SCT is the best treatment,
while in patients older than 40 years IST gives the best
results.40 The advantage of transplantation compared
with IST in younger, severely affected patients is probably
due to a shorter time of improvement of blood counts
which is especially favourable in those with a severe low
number of neutrophils. The advantage for IST in older
patients is probably caused by the increased mortality of
allo-SCT in this group. However, the difference in advan-
tage for IST in older patients decreases in time, probably
Sleijfer, et al. Aplastic anaemia: a review.
M A Y  2 0 0 3 ,  V O L .  6 1 ,  N O .  5
161
Table 3
Results of trials comparing IST with allo-SCT for the treatment of aplastic anaemia – follow-up for survival differs
IST ALLO-SCT
AUTHOR AGE (YEARS) N SURVIVAL (%) N SURVIVAL (%)
Speck49 All ages 32 69 18 44
Bayever50 <25 22 45 35 72
Halperin51 <18 12 25 14 79
Locasciulli52 <15 133 48 171 63*
Paquette53 Adults 146 49 55 72
IST = immunosuppressive therapy, allo-SCT = allogeneic stem cell transplantation.* Significant difference (p<0.05).
due to relapses and the increased incidence of cancer.
In patients aged up to 40 years and with a moderately
affected neutrophil number there is no clear difference in
five-year survival in favour of either of the treatment
options.40 However, because of the increased long-term
effects of IST compared with allo-SCT, the latter is to be
preferred.
So, in our institute, this has accumulated in the protocol
as depicted in table 4.
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Table 4
First, second, and third-line therapy for aplastic anaemia
in the Erasmus Medical Centre
NEUTROPHILS <0.2 x 109/l NEUTROPHILS >0.2 x 109/l
Age <45 years Age <20 years
1. sib-SCT 1. sib-SCT
2. IST 2. IST
3. MUD-SCT 3. MUD-SCT
Age ≥45 years: Age ≥20 years
1. IST 1. IST
2. sib-SCT (<55 years) 2. sib-SCT (<55 years)
3. MUD-SCT (<50 years) 3. MUD-SCT (<50 years)
sib-SCT = allogeneic stem cell transplantation from HLA-identical sibling,
IST = immunosuppressive therapy, MUD-SCT = allogeneic stem cell
transplantation from matched unrelated donor.
C O N C L U S I O N
During the last decades, insight in the pathogenesis of
aplastic anaemia has increased. In parallel with this, the
prognosis of this potentially fatal disorder has improved
radically. It can be expected that responses to IST will
probably continue to rise partly due to new drugs tested
for their efficacy in aplastic anaemia, such as myco-
phenolate mofetil, rapamycin, and monoclonals against
the interleukin-2 receptor. Also results of allo-SCT will
probably improve by better supportive care, more effective
GVHD prophylaxis and less toxic conditioning regimens.
This improvement of treatments urges that recommen-
dations for treating aplastic anaemia will continue to be
defined.
A C K N O W L E D G E M E N T
The authors wish to thank Dr. K. Lam, Department of
Pathology, Erasmus Medical Centre, for providing the figures.
20. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon- and
tumor necrosis factor- suppress both early and late stages of hematopoiesis
and induce programmed cell death. J Cell Physiol 1995;165:538-46.
21. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased
expression of Fas antigen on bone marrow CD34+ cells of patients with
aplastic anaemia. Br J Haematol 1995;91:245-51.
22. Wolk A, Simon-Stoos K, Nami I, et al. A mouse model of immune-medi-
ated aplastic anemia. Blood 1998;suppl 92:abstr 639.
23. Calado RT, Garcia AB, Gallo DP, et al. P-glycoprotein function is impaired
in CD34+ cells from patients with aplastic anemia. Blood 
2001;suppl 98:abstr 933.
24. Vulliamy T, Marrone A, Dokal I, Mason PJ. Association between aplastic
anaemia and mutations in telomerase RNA. Lancet 2002;359:2168-9.
25. Bacigalupo A, Oneto R, Bruno B, et al. Current results of bone marrow
transplantation in patients with acquired severe aplastic anemia. Acta
Haematol 2000;103:19-25.
26. Mathe G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man
after conditioning by antilymphocytic serum. BMJ 1970;2:131-6.
27. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in
patients with aplastic anemia: a prospective randomized trial. N Engl J
Med 1983;308:113-8.
28. Camitta B, O’Reilly RJ, Sensenbrenner LL, et al. Antithoracic duct lymphocyte
globulin therapy of severe aplastic anemia. Blood 1983;62:883-8.
29. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP. Do
androgens enhance the response to antithymocyte globulin in patients
with aplastic anemia? A prospective randomized trial. Blood 1985;66:184-8.
30. Doney K, Martin P, Storb R, Appelbaum FR. A randomized trial of antihuman
thymocyte globulin versus murine monoclonal antihuman T-cell antibodies
as immunosuppressive therapy for aplastic anemia. Exp Haematol
1985;13:520-4.
31. Kaltwasser JP, Dix U, Schalk KP, Vogt H. Effect of androgens on the
response to antithymocyte globulin in patients with aplastic anemia.
Eur J Haematol 1988;40:111-8.
32. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic
anemia with antilymphocyte globulin and methylprednisolone with or
without cyclosporin. N Engl J Med 1991;324:1297-304.
33. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized
study comparing cyclosporine-A alone and antithymocyte globulin with
prednisone for treatment for severe aplastic anemia. Blood 1992;79:2540-6.
34. Doney K, Pepe M, Strob R, et al. Immunosuppressive therapy for aplastic
anemia: results of a prospective, randomized trail of antithymocyte globulin
(ATG), methylprednisolone, and oxymetholone to ATG, very high dose
methylprednisolone, and oxymetholone. Blood 1992;79:2566-71.
35. Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia
(AA) with antilymphocyte globulin (ALG) and methylprednisolone
(Mpred) with or without androgens: a randomised trial from the EBMT
SAA working group. Br J Haematol 1993;83:145-51.
36. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized
multicenter study comparing cyclosporin alone versus the combination
of antithymocyte globulin and cyclosporin for treatment with patients
with nonsevere aplastic anemia. Blood 1999;93:2191-5.
37. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using
antithymocyte globulin, cyclosporine, and danazol with or without human
granulocyte colony-stimulating factor in children with acquired aplastic
anemia. Blood 2000;96:2049-54.
38. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in
severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-9.
39. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe
aplastic anemia: bone marrow transplantation compared with
immunosuppressive therapy. Semin Hematol 2000;37:69-80.
40. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse
anti-lymphocyte globulin for severe aplastic anaemia. Br J Haematol
1998;100:393-400.
41. Kinoshita T, Inoue N. Relationship between aplastic anemia and paroxysmal
nocturnal hemoglobinuria. Int J Hematol 2002;75:117-22.
42. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal
hemoglobinuria in patients with bone marrow failure syndromes. Ann
Intern Med 1999;131:401-8.
43. Araten DJ, Nafa K, Pakdeesuwan K, Luzatto L. Clonal populations of
hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype
and phenotype are present in normal individuals. Proc Natl Acad Sci
USA 1999;96:5209-14.
44. Chen R, Nagarajan S, Prince GM, et al. Impaired growth and elevated fas
receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal
hemoglobinuria. J Clin Invest 2000;106:689-96.
45. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring
after treatment of aplastic anemia. N Engl J Med 1993;329:1152-7.
46. Doney K, Leisenring W, Storb R, et al. Primary treatment of acquired
aplastic anemia: outcomes with bone marrow transplantation and
immunosuppressive therapy. Ann Intern Med 1997;126:107-15.
47. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC.
Progressive telomere shortening in aplastic anemia. Blood 
1998;91:3582-92.
48. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of
acquired aplastic anemia into myelodysplastic syndrome and acute
myeloid leukemia after immunosuppressive therapy in children. Blood
2002;100:786-90.
49. Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic
anaemia with antilymphocyte globulin or bone-marrow transplantation.
BMJ 1981;282:860-3.
50. Bayever E, Champlin R, Ho W, et al. Comparison between bone marrow
transplantation and antithymocyte globulin in treatment of young
patients with severe aplastic anemia. J Pediatr 1984;105:920-5.
51. Halperin DS, Grisaru D, Freedman MH, Saunders EF. Severe acquired
aplastic anemia in children: 11 year experience with bone marrow
transplantation and immunosuppressive therapy. Am J Pediatr Hematol
Oncol 1989;11:304-9.
52. Locasciulli A, Veer L van ‘t, Bacigalupo A, et al. Treatment with bone marrow
transplantation or immunosuppression of childhood acquired severe
aplastic anemia: a report from the EBMT SAA Working Party. Bone
Marrow Transplant 1990;6:211-7.
53. Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic
anemia in adults treated with antithymocyte globulin: comparison with
bone marrow transplantation. Blood 1995;85:283-90.
Sleijfer, et al. Aplastic anaemia: a review.
M A Y  2 0 0 3 ,  V O L .  6 1 ,  N O .  5
163
